❯ Anthropic IPO draws orders several times the shares available as bankers consider a valuation of $1.5 trillion or more

Large orders arrive earlyDemand for Anthropic’s planned listing has strengthened soon after the roadshow began. Bloomberg reported on November 11 that indications of interest amounted to several times the available shares, driven primarily by large institutional orders; the exact multiple was not disclosed. Marketing continues, and the final price, allocations and proceeds have not been determined.

The filed offering takes shapeClaude developer Anthropic launched its IPO roadshow on November 10, proposing 825 million Class A shares at $70–$78 each and applying to list on Nasdaq as ANT. About 801.35 million shares would be sold by the company and 23.65 million by existing shareholders, whose proceeds would not go to Anthropic. At the range’s upper end, the base share sale would total approximately $64.35 billion, with an additional underwriter option available.

Bankers consider a higher priceAccording to Yahoo Finance’s account of Financial Times reporting, strong interest has prompted bankers to consider pricing above the filed range, potentially taking the fully diluted valuation to $1.5 trillion or more. That measure includes potential shares such as equity options; the current range’s upper end implies roughly $1.4 trillion. A higher price remains under discussion, and the reported talks do not themselves amend the announced $70–$78 range.

Capital for computing capacityThe listing also includes a planned $26 billion private placement. Bloomberg, citing filings, puts the combined IPO and placement at up to $90.4 billion, a total that includes existing shareholders’ sales. Coverage of the Financial Times report says Anthropic wants additional funds for computing expenditure. Cash available for operations determines how much capacity it can secure for training models and serving Claude, so a higher corporate valuation and money actually received by the business are distinct outcomes.

The pitch reaches into medicineIn the roadshow video released on November 10, Dario Amodei predicted that cancer, Alzheimer’s, heart disease and mental illness could become problems of the past within a decade. Business Insider reported objections from medical professionals who see potential for AI in research but dispute that sweeping timetable. It also noted that Anthropic has begun drug discovery work; those efforts and Amodei’s forecast are not demonstrated treatment outcomes.

Investor meetings continueBloomberg says Amodei and JPMorgan Chase CEO Jamie Dimon are scheduled for an investor livestream on Friday, November 13, while Goldman Sachs and Morgan Stanley lead the offering. Demand gives the banks room to consider adjusting terms, but indications of interest still need to become final allocations, and neither the IPO nor the accompanying financing has closed. Public investors will also assess how Claude’s existing business supports continuing investment and how longer-term medical research might eventually produce commercial results.

▮ SIGNALInstitutional demand strengthens Anthropic’s ability to finance computing expansion, while its medical ambitions extend public expectations well beyond revenue from its models.